Analysis of pulsed cisplatin signalling dynamics identifies effectors of resistance in lung adenocarcinoma

Jordan F Hastings,Alvaro Gonzalez Rajal,Sharissa L Latham,Jeremy Zr Han,Rachael A McCloy,Yolande Ei O'Donnell,Monica Phimmachanh,Alexander D Murphy,Adnan Nagrial,Dariush Daneshvar,Venessa Chin,D Neil Watkins,Andrew Burgess,David R Croucher

DOI: https://doi.org/10.7554/eLife.53367

IF: 7.7

2020-06-09

eLife

Abstract:The identification of clinically viable strategies for overcoming resistance to platinum chemotherapy in lung adenocarcinoma has previously been hampered by inappropriately tailored in vitro assays of drug response. Therefore, using a pulse model that closely mimics the in vivo pharmacokinetics of platinum therapy, we profiled cisplatin-induced signalling, DNA-damage and apoptotic responses across a panel of human lung adenocarcinoma cell lines. By coupling this data to real-time, single-cell imaging of cell cycle and apoptosis we provide a fine-grained stratification of response, where a P70S6K-mediated signalling axis promotes resistance on a TP53 wildtype or null background, but not a mutant TP53 background. This finding highlights the value of in vitro models that match the physiological pharmacokinetics of drug exposure. Furthermore, it also demonstrates the importance of a mechanistic understanding of the interplay between somatic mutations and the signalling networks that govern drug response for the implementation of any consistently effective, patient-specific therapy.